Naturalized U.S. citizen, 2000. B.S. ﴾Biochemistry﴿ University of Stirling, Scotland, 1982. Ph.D ﴾Biochemistry﴿, Oxford University, 1985. Postdoctoral Fellow, Stanford University, 1985‐2000. Assistant professor, University of California San Diego 1990‐ 1995; associate professor, 1995‐1999; professor, 1999‐2008; CHAIR, CELL AND DEVELOPMENTAL BIOLOGY, CENTRE FOR GENOMIC REGULATION, 2008‐. Recipient: Pirie‐Reid Scholarship, Oxford University; Damon‐Runyon Walter‐Winchell Postdoctoral Fellowship; American Cancer Society ﴾California Division﴿ Senior Postdoctoral Fellowship; Basil O'Connor Starter Scholars Award; Established investigator of the American Heart Association; senior investigator award from the Sandler’s program for asthma research; Elected fellow AAAS, 2005. Elected member EMBO 2009. ASBMB‐MERCK award 2013. Editorial board: Cell 1995‐2001; MBOC 1999‐ 2015; JCB 2007‐. Curr. Opin. Cell Biol 2008‐2014; Senior editor: eLife 2014‐; Miller visiting professor, UC Berkeley, 2016; elected ASCB fellow, 2018. NGBT, excellence in science award ﴾India﴿ 2019; Humboldt research award, Germany ﴾2020﴿; ERC advanced grant ﴾ 2011‐2016﴿; Red Bird Visiting professor, Institute of Advanced studies, Hong Kong University of Science and Technology (2023); ERC Synergy grant ﴾2020‐2027﴿. STATEMENT OF ACCOMPLISHMENTS Malhotra elucidated how the Golgi complex is partitioned during cell division, revealing this to be a cell‐cycle check point. In a systematic search for drugs that could provide starting points for mechanistic analysis, Malhotra discovered a natural product, Ilimaquinone ﴾IQ﴿, that massively vesiculates the Golgi at interphase to resemble the mitotic state. Pursuing the mechanism of action of IQ led Malhotra to elucidate a novel paradigm for vesicle biogenesis in which a kinase signaling cascade results in activation of a phospholipase to generate a local excess of diacylglycerol which physically drives vesicle budding. This was the first demonstration of how vesicles of variable sizes can be created. Malhotra next performed genome‐wide screens to uncover new components of the cells’ secretory apparatus. He discovered the TANGO1 gene family needed to selectively sort and package large and complex cargoes like collagens and chylomicrons for export from the endoplasmic reticulum. Malhotra went on to dissect TANGO1’s mechanism of action, ultimately solving a long‐standing problem of how cells can make “made‐to‐measure” transport intermediates capable of packaging and secreting cargos bigger than the “one size fits all” COPII vesicles. Another TANGO gene revealed a unique calcium‐based cargo sorting pathway at the Golgi complex. Malhotra has been a pioneer uncovering the essential machinery and mechanisms for protein secretion from specialized human cells including; mucin secretion from goblet cells in the lung and collagen secretion from skin cells. He also leads our understanding of how proteins that cannot enter the conventional ER‐Golgi pathway are exported.

Professor Chiara Zurzolo, MD, PhD, is head of the Membrane Trafficking and Pathogenesis Unit and co-director of the Brain connectivity and neurodegenerative diseases research program at the Institut Pasteur (Paris). She received her MD and then PhD in molecular and cell biology from the University of Naples Federico II. She then obtained a postdoctoral fellowship to spend four years at Cornell Medical School, New York where she uncovered some of the mechanisms of apical protein trafficking in polarized epithelial cells. In 1995, she returned to Naples to establish her laboratory at the Faculty of Medicine and Surgery at Naples University “Federico II” as a professor of cell biology. In 2003, she became director of research at the Institut Pasteur in Paris where she studies the mechanisms of protein trafficking in health and diseases with a focus on neurodegenerative diseases and brain tumors. They have uncovered mechanisms of apical sorting in polarized epithelial cells and pioneered the field of tunneling nanotubes, (TNTs), revealing their structure, and their role in the intercellular spreading of amyloid proteins in neurodegenerative diseases and cancer, as well as their role in viral spreading. In 2015, she was elected member of the European Molecular Biology Organization (EMBO) and promoted Professor at Institut Pasteur. In 2019, she was a visiting scholar at Harvard University, sponsored by the prestigeous Radcliffe Fellowship award. In 2023 she has been elected Member of Academia Europea. https://research.pasteur.fr/en/member/chiara-zurzolo/ https://www.radcliffe.harvard.edu/people/chiara-zurzolo

I am an assistant professor in the Department of Physiology at Gyeongsang National University College of Medicine. My research interests focus on identifying novel cellular stress markers and elucidating the mechanisms linking cellular stress responses to the onset and progression of various diseases, including cancer and neurodegenerative disorders.

Dr. Chulhee Choi is the founder of ILIAS Biologics, Inc. and a recognized pioneer in exosome-based protein drug delivery systems. ILIAS Biologics was established as a spin-off from KAIST (Korea Advanced Institute of Science and Technology), where Dr. Choi has served as a Professor in the Department of Bio and Brain Engineering and formerly as the Chair of the Optical Bioimaging Center. Dr. Choi has authored over 150 peer-reviewed publications in leading scientific journals and holds more than 40 international patents, including key intellectual property related to exosome-based platform technologies for intracellular protein delivery—technologies that form the foundation of ILIAS Biologics. He received his M.D. in Medicine and Ph.D. in Microbiology from Yonsei University College of Medicine.